Detection of Latent Tuberculosis Infection in Patients with Rheumatological Diseases Who Receive Immunosuppressive Therapy
Authors:
- Anna StarshinovaAnna Starshinova
- Adilia SabirovaASAdilia Sabirova
- Alexey MaslyanskiyAMAlexey Maslyanskiy
- Irina GrigorievaIGIrina Grigorieva
- Raul SharipovRSRaul Sharipov
- Ravil TukfatullinRTRavil Tukfatullin
- Aleksandr PanteleevAPAleksandr Panteleev
- Michail NazarenkoMNMichail Nazarenko
- Dmitry KudlayDKDmitry Kudlay
Open Access
- 17 June 2026
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 16 (12) , 1883
Abstract
Background/Objectives: Latent tuberculosis infection (LTBI) is a persistent immune response to Mycobacterium tuberculosis antigens in the absence of clinically active tuberculosis. It is now established that progression from LTBI to active tuberculosis is directly associated with immune dysregulation, which frequently occurs in immune-mediated diseases requiring treatment with immunosuppressive agents. The aim of this study was to identify LTBI in patients with rheumatological diseases receiving immunosuppressive therapy using contemporary immunodiagnostic methods. Materials and Methods: A retrospective, prospective, group-control study was conducted, analyzing the results of immunodiagnostics in patients with rheumatological diseases on immunosuppressive therapy and without established contact with tuberculosis patients (n = 44; main group). The control group consisted of healthy individuals (n = 51) with no history of tuberculosis contact, clinical or radiological manifestations of the disease, or signs of chronic pathology exacerbation. Both groups were predominantly female (72.7% in the main group and 62.8% in the control group). The mean age in the patient group was 49.1 years (95% CI [44.77; 53.43]). Rheumatoid arthritis was diagnosed in 29.6% (13) of patients (95% CI [16.06; 43.03]). Articular syndrome was observed in at least 72.7% (32) of patients (95% CI [59.57; 85.89]). In 54.6% (24) of cases (95% CI [39.83; 69.26]), patients received biologic immunosuppressive therapy as basic treatment. In 15.9% (7) of cases (95% CI [5.10; 26.72]), patients received conventional synthetic disease-modifying antirheumatic drugs (DMARDs). Of these, 71.43% (5) (95% CI [35.24; 92.44]) underwent comprehensive examination to exclude active tuberculosis prior to biologic therapy initiation. For immunodiagnostics, all subjects underwent an interferon-gamma release assay (IGRA) and/or testing with a recombinant tuberculosis antigen (ATR) sample, with dynamic assessment of test results. All patients with positive immunodiagnostic results underwent multidetector computed tomography of the chest organs. The level of LTBI in the comparison groups was defined as the percentage of positive immunological test results at a significance level of p < 0.05. Statistical data processing was performed using Microsoft Excel 2019. Results: In the main group, positive immunodiagnostic results were recorded in 20.5% (9) of cases (95% CI [8.54; 32.37]), which is significantly higher than in the control group of healthy individuals (5.8% (3), 95% CI [1.41; 16.54]). This reflects statistically significant differences in immunological test results between groups receiving and not receiving immunosuppressive therapy (χ2 = 4.545, p = 0.034). Dynamic evaluation of the ATR sample revealed positive results in 21.7% (5) of cases (95% CI [4.88; 38.60]), with four out of five patients demonstrating positive conversion. In the third assessment, positivity was observed in 33.33% (5) of cases (95% CI [9.48; 57.19]), which was higher than in the first (χ2 = 1.025, p = 0.312) and second assessments (χ2 = 0.629, p = 0.428), although these differences were not statistically significant. Notably, in two out of five patients, the ATR test result changed from negative to positive. Conclusions: In patients with rheumatological diseases receiving immunosuppressive therapy, LTBI was detected in 20.5%, which is significantly higher than in healthy individuals (5.8%, p = 0.034). Furthermore, there was an increase in the proportion of positive tests over time (up to 21.7% and 33.3% on immunotherapy), suggesting an increasing risk of progression to active tuberculosis infection.Keywords
Funding Information
- Ministry of Science and Higher Education of the Russian Federation (075-15-2025-013)
This publication has 27 references indexed in Scilit:
- Safety of interleukin-17A inhibitors in 306 patients with psoriasis with or without latent tuberculosis: a dual-centre retrospective study in ChinaClinical and Experimental Dermatology, 2025
- Assessment and management for latent tuberculosis before advanced therapies for immune-mediated inflammatory diseases: A comprehensive reviewAutoimmunity Reviews, 2025
- Evaluation of serial QuantiFERON‐TB Gold in tube test results and tuberculosis infection status in patients with psoriasis receiving anti‐IL‐17 treatment (secukinumab and ixekizumab): Real‐world data from a tuberculosis‐endemic countryAustralasian Journal of Dermatology, 2024
- The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapyJournal of Infection and Public Health, 2024
- Latent tuberculosis prevalence, diagnosis and treatment in Multiple Sclerosis as a strategy for reducing infection reactivation during immunosuppressant therapyMultiple Sclerosis and Related Disorders, 2024
- Screening, prophylaxis, and challenges: Tumor necrosis factor inhibitors and latent tuberculosis infection nexus in rheumatologyInternational Journal of Rheumatic Diseases, 2023
- Latent tuberculosis infection in myasthenia gravis patients on immunosuppressive therapy: high incidence yet moderate reactivation rateAnnals of Medicine, 2023
- Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologicsExpert Review of Clinical Immunology, 2020
- Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort studyThe Lancet Infectious Diseases, 2015
- THE PROGNOSIS OF A POSITIVE TUBERCULIN REACTION IN CHILDHOOD AND ADOLESCENCEAmerican Journal of Epidemiology, 1974